Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 1
Emerging Updates in Front-line Treatment Approach of DLBCL
Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.
Video Player is loading.
Video content above is prompted by the following:
- Discuss treatment strategies for newly diagnosed DLBCL.
- What factors are most important when selecting treatments for 1L DLBCL?
- What are unmet needs in 1L treatment options in DLBCL.
- With the 2024 NCCN update concerning Pola+R-CHP in DLBCL, how is your standard approach to 1L treatment of DLBCL evolving?
- How does the prolonged follow-up from POLARIX change your view on how and when to use POLA+R-CHP?
- What advice would you give to community practitioners when using this style of treatment?